Quantcast
Last updated on April 16, 2014 at 12:11 EDT

Elsevier Announces 2012 Journal Impact Factor Highlights

July 15, 2013

AMSTERDAM, July 15, 2013 /PRNewswire/ –

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced the highlights of its
journal Impact Factor performance in 2012. According to the 2012 Journal Citation
Reports(R) (JCR) published by Thomson Reuters, Elsevier saw 53% of its journal Impact
Factors increase from 2011 to 2012. Furthermore, 17% of Elsevier journals are in the top
10% of their subject category, well ahead of its major commercial competitors.

Elsevier journals top the rankings in 59 subject categories, up from 57 in 2011. Of
Elsevier’s 1,600 journals in the JCR, 44% are in the top 25% of their subject category. In
2012, 15 Elsevier journals have risen to the top of their subject category, including
Cell, reclaiming the top position in “Biochemistry & Molecular Biology”.

“Another year of positive results reinforces my view that we’re on the right track as
a publisher, but most of the credit should go to the world-class authors, editors and
reviewers”, said Philippe Terheggen, Managing Director Journals at Elsevier. “When we look
at these scores, it’s important to keep in mind that while the Impact Factor is an
important measure for overall journal influence, it is not to be used for evaluation of
individual researchers or articles. We’re increasingly looking at additional metrics,
including so called Altmetrics, as a measure of influence of journals and authors.
Meanwhile, we will continue to invest in enhancing the quality of our content, for example
by increased support of peer review, by enriching the online article, and through linking
articles to research data sets in external repositories. That’s the journey we’re on.”

Flagship titles and society journals

All of The Lancet [http://www.thelancet.com ] journals’ Impact Factors increased. The
Lancet rose from 38.278 to 39.060, The Lancet Oncology saw an increase from 22.589 to
25.117 moving up its subject category ranking from 4th to 3rd position. The Lancet
Neurology increased to 23.917, from 23.462, and The Lancet Infectious Diseases went up
from 17.391 to 19.966, both journals maintaining the top rankings in their respective
categories.

The journals of Cell Press [http://www.cell.com/cellpress ], an imprint of Elsevier,
mostly saw quite stable trends in Impact Factor, with highlights including strong growth
from Molecular Cell – an 8% increase to 15.280 and Trends in Cognitive Sciences, which saw
a 27% increase in comparison to 2011, to 16.008. Its flagship journal Cell continues to
lead in its field with an impact factor of 31.957, and is the number one research journal
in the Cell Biology and Biochemistry & Molecular Biology categories.

Of the 420 titles in the JCR that Elsevier publishes on behalf of societies, 261, or
62%, showed a rise in their Impact Factors. Nine of these rank number one in their subject
categories, among which Evolution and Human Behavior, rising from the 4th position in the
category “Social Sciences, Biomedical”. Two society journals reached a number one position
for the first time: European Urology reached the number one position in “Urology &
Nephrology, and Forensic Science International: Genetics ranked highest in the category:
“Medicine, Legal”.

The Impact Factor helps evaluate a journal’s impact compared to others in the same
field by measuring the frequency with which recent articles in a journal have been cited
in a particular year: the 2012 Impact Factor takes into account citations in 2012 to
papers published in 2010 and 2011.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical information
products and services. The company works in partnership with the global science and health
communities to publish more than 2,000 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and close to 20,000 book
titles, including major reference works from Mosby and Saunders. Elsevier’s online
solutions include ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Reaxys [http://www.elsevier.com/reaxys ], ClinicalKey
[https://www.clinicalkey.com ] and Mosby’s Suite [http://www.confidenceconnected.com ],
which enhance the productivity of science and health professionals, and the SciVal suite
[http://www.scival.com ] and MEDai’s Pinpoint Review [http://www.medai.com ], which help
research and health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier [http://www.elsevier.com ]
employs 7,000 people worldwide. The company is part of Reed Elsevier Group plc
[http://www.reedelsevier.com/Pages/Home.aspx ], a world leading provider of professional
information solutions. The group employs more than 30,000 people, including more than
15,000 in North America. Reed Elsevier Group plc is owned equally by two parent companies,
Reed Elsevier PLC and Reed Elsevier NV. Their shares are traded on the London, Amsterdam
and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam:
REN; New York: RUK and ENL.

        Media contact
        Tom Reller
        Vice President, Global Corporate Relations, Elsevier
        +1-215-239-3508
        t.reller@elsevier.com

SOURCE Elsevier


Source: PR Newswire